Increase of Peroxisome Proliferator-activated Receptor δ (PPARδ) by Digoxin to Improve Lipid Metabolism in the Heart of Diabetic Rats

 

 Buy Article Permissions and Reprints

Abstract

Increase of peroxisome proliferator-activated receptor δ (PPARδ) expression by digoxin in the heart of diabetic rats has been documented. The present study investigated the mediation of PPARδ in lipid metabolism improved by digoxin in the heart of diabetic rats and in the hyperglycemia-treated cardiomyocytes using the primary cultured cardiomyocytes from neonatal rat. The lipid deposition within the heart section was assessed in diabetic rats by oil red O staining. The fatty acid oxidation genes in cardiomyocytes were also examined. Inhibitor of calcium ions and siRNA-PPARδ were employed to investigate the potential mechanisms. After a 20-day digoxin treatment, the PPARδ expression was elevated in hearts of diabetic rats while the cardiac lipid deposition was reduced. In neonatal cardiomyocytes, digoxin also caused an increase in expressions of PPARδ and fatty acid oxidation genes. But both actions of digoxin were blocked by BAPTA-AM to chelate calcium ions and by siRNA-PPARδ in cardiomyocytes. The obtained results show that increase of PPARδ by digoxin is related to regulation of fatty acid oxidation genes in cardiac cells mediated by calcium-triggered signals.

• References

• 1 Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 1974; 34: 29-34
  CrossrefPubMedGoogle Scholar
• 2 Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979; 241: 2035-2038
  CrossrefPubMedGoogle Scholar
• 3 Malmberg K, Ryden L. Myocardial infarction in patients with diabetes mellitus. Eur Heart J 1988; 9: 259-264
  PubMedGoogle Scholar
• 4 Herlitz J, Malmberg K, Karlson BW, Ryden L, Hjalmarson A. Mortality and morbidity during a five-year follow-up of diabetics with myocardial infarction. Acta Med Scand 1988; 224: 31-38
  PubMedGoogle Scholar
• 5 Poornima IG, Parikh P, Shannon RP. Diabetic cardiomyopathy: the search for a unifying hypothesis. Circ Res 2006; 98: 596-605
  CrossrefPubMedGoogle Scholar
• 6 An D, Rodrigues B. Role of changes in cardiac metabolism in development of diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol 2006; 291: H1489-H1506
  CrossrefPubMedGoogle Scholar
• 7 Besch Jr HR, Watanabe AM. The positive inotropic effect of digitoxin: independence from sodium accumulation. The Journal of pharmacology and experimental therapeutics 1978; 207: 958-965
  PubMedGoogle Scholar
• 8 Pervaiz MH, Dickinson MG, Yamani M. Is digoxin a drug of the past?. Cleve Clin J Med 2006; 73: 821-824 826, 829–832 passim
  CrossrefPubMedGoogle Scholar
• 9 van Veldhuisen DJ, Man in ’t Veld AJ, Dunselman PH, Lok DJ, Dohmen HJ, Poortermans JC, Withagen AJ, Pasteuning WH, Brouwer J, Lie KI. Double-blind placebo-controlled study of ibopamine and digoxin in patients with mild to moderate heart failure: results of the Dutch Ibopamine Multicenter Trial (DIMT). J Am Coll Cardiol 1993; 22: 1564-1573
  CrossrefPubMedGoogle Scholar
• 10 Ahmed A, Pitt B, Rahimtoola SH, Waagstein F, White M, Love TE, Braunwald E. Effects of digoxin at low serum concentrations on mortality and hospitalization in heart failure: a propensity-matched study of the DIG trial. Int J Cardiol 2008; 123: 138-146
  CrossrefPubMedGoogle Scholar
• 11 Yang Q, Li Y. Roles of PPARs on regulating myocardial energy and lipid homeostasis. J Mol Med 2007; 85: 697-706
  CrossrefPubMedGoogle Scholar
• 12 Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990; 347: 645-650
  CrossrefPubMedGoogle Scholar
• 13 Cheng L, Ding G, Qin Q, Huang Y, Lewis W, He N, Evans RM, Schneider MD, Brako FA, Xiao Y, Chen YE, Yang Q. Cardiomyocyte-restricted peroxisome proliferator-activated receptor-delta deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy. Nat Med 2004; 10: 1245-1250
  CrossrefPubMedGoogle Scholar
• 14 Cheng L, Ding G, Qin Q, Xiao Y, Woods D, Chen YE, Yang Q. Peroxisome proliferator-activated receptor delta activates fatty acid oxidation in cultured neonatal and adult cardiomyocytes. Biochem Biophys Res Commun 2004; 313: 277-286
  CrossrefPubMedGoogle Scholar
• 15 Barish GD, Narkar VA, Evans RM. PPAR delta: a dagger in the heart of the metabolic syndrome. J Clin Invest 2006; 116: 590-597
  CrossrefPubMedGoogle Scholar
• 16 Planavila A, Rodriguez-Calvo R, Jove M, Michalik L, Wahli W, Laguna JC, Vazquez-Carrera M. Peroxisome proliferator-activated receptor beta/delta activation inhibits hypertrophy in neonatal rat cardiomyocytes. Cardiovasc Res 2005; 65: 832-841
  CrossrefPubMedGoogle Scholar
• 17 Pesant M, Sueur S, Dutartre P, Tallandier M, Grimaldi PA, Rochette L, Connat JL. Peroxisome proliferator-activated receptor delta (PPARdelta) activation protects H9c2 cardiomyoblasts from oxidative stress-induced apoptosis. Cardiovasc Res 2006; 69: 440-449
  CrossrefPubMedGoogle Scholar
• 18 Finck BN, Kelly DP. Peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1) regulatory cascade in cardiac physiology and disease. Circulation 2007; 115: 2540-2548
  CrossrefPubMedGoogle Scholar
• 19 Rimbaud S, Garnier A, Ventura-Clapier R. Mitochondrial biogenesis in cardiac pathophysiology. Pharmacol Rep 2009; 61: 131-138
  PubMedGoogle Scholar
• 20 Yu BC, Chang CK, Ou HY, Cheng KC, Cheng JT. Decrease of peroxisome proliferator-activated receptor delta expression in cardiomyopathy of streptozotocin-induced diabetic rats. Cardiovasc Res 2008; 80: 78-87
  CrossrefPubMedGoogle Scholar
• 21 Ventura-Clapier R, Garnier A, Veksler V. Transcriptional control of mitochondrial biogenesis: the central role of PGC-1alpha. Cardiovasc Res 2008; 79: 208-217
  CrossrefPubMedGoogle Scholar
• 22 Sack MN, Kelly DP. The energy substrate switch during development of heart failure: gene regulatory mechanisms (Review). Int J Mol Med 1998; 1: 17-24
  PubMedGoogle Scholar
• 23 Bugger H, Abe ED. Molecular mechanisms for myocardial mitochondrial dysfunction in the metabolic syndrome. Clin Sci 2008; 114: 195-210
  CrossrefPubMedGoogle Scholar
• 24 Fein FS, Kornstein LB, Strobeck JE, Capasso JM, Sonnenblick EH. Altered myocardial mechanics in diabetic rats. Circ Res 1980; 47: 922-933
  CrossrefPubMedGoogle Scholar
• 25 Fein FS, Strobeck JE, Malhotra A, Scheuer J, Sonnenblick EH. Reversibility of diabetic cardiomyopathy with insulin in rats. Circ Res 1981; 49: 1251-1261
  CrossrefPubMedGoogle Scholar
• 26 Chen ZC, Yu BC, Chen LJ, Cheng KC, Lin HJ, Cheng JT. Characterization of the mechanisms of the increase in PPARdelta expression induced by digoxin in the heart using the H9c2 cell line. Br J Pharmacol 2011; 163: 390-398
  CrossrefPubMedGoogle Scholar
• 27 Naya FJ, Mercer B, Shelton J, Richardson JA, Williams RS, Olson EN. Stimulation of slow skeletal muscle fiber gene expression by calcineurin in vivo. J Biol Chem 2000; 275: 4545-4548
  CrossrefPubMedGoogle Scholar
• 28 Passier R, Zeng H, Frey N, Naya FJ, Nicol RL, McKinsey TA, Overbeek P, Richardson JA, Grant SR, Olson EN. CaM kinase signaling induces cardiac hypertrophy and activates the MEF2 transcription factor in vivo. J Clin Invest 2000; 105: 1395-1406
  CrossrefPubMedGoogle Scholar
• 29 Schiaffino S, Serrano A. Calcineurin signaling and neural control of skeletal muscle fiber type and size. Trends Pharmacol Sci 2002; 23: 569-575
  CrossrefPubMedGoogle Scholar
• 30 Hokanson JF, Mercier JG, Brooks GA. Cyclosporine A decreases rat skeletal muscle mitochondrial respiration in vitro. Am J Respir Crit Care Med 1995; 151: 1848-1851
  CrossrefPubMedGoogle Scholar
• 31 Zhou L, Cabrera ME, Okere IC, Sharma N, Stanley WC. Regulation of myocardial substrate metabolism during increased energy expenditure: insights from computational studies. Am J Physiol Heart Circ Physiol 2006; 291: H1036-H1046
  CrossrefPubMedGoogle Scholar
• 32 Shkryl VM, Shirokova N. Transfer and tunneling of Ca2+ from sarcoplasmic reticulum to mitochondria in skeletal muscle. J Biol Chem 2006; 281: 1547-1554
  PubMedGoogle Scholar
• 33 Schaeffer PJ, Wende AR, Magee CJ, Neilson JR, Leone TC, Chen F, Kelly DP. Calcineurin and calcium/calmodulin-dependent protein kinase activate distinct metabolic gene regulatory programs in cardiac muscle. J Biol Chem 2004; 279: 39593-39603
  CrossrefPubMedGoogle Scholar
• 34 Tate CA, Hyek MF, Taffet GE. The role of calcium in the energetics of contracting skeletal muscle. Sports Med 1991; 12: 208-217
  CrossrefPubMedGoogle Scholar
• 35 Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 1996; 137: 354-366
  CrossrefPubMedGoogle Scholar
• 36 Takahashi S, Tanaka T, Sakai J. New therapeutic target for metabolic syndrome: PPARdelta. Endocr J 2007; 54: 347-357
  CrossrefPubMedGoogle Scholar
• 37 Wang YX, Zhang CL, Yu RT, Cho HK, Nelson MC, Bayuga-Ocampo CR, Ham J, Kang H, Evans RM. Regulation of muscle fiber type and running endurance by PPARdelta. PLoS Biol 2004; 2: e294
  CrossrefPubMedGoogle Scholar
• 38 Lin J, Wu H, Tarr PT, Zhang CY, Wu Z, Boss O, Michael LF, Puigserver P, Isotani E, Olson EN, Lowell BB, Bassel-Duby R, Spiegelman BM. Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres. Nature 2002; 418: 797-801
  CrossrefPubMedGoogle Scholar
• 39 Luquet S, Lopez-Soriano J, Holst D, Fredenrich A, Melki J, Rassoulzadegan M, Grimaldi PA. Peroxisome proliferator-activated receptor delta controls muscle development and oxidative capability. FASEB J 2003; 17: 2299-2301
  PubMedGoogle Scholar
• 40 Kleiner S, Nguyen-Tran V, Bare O, Huang X, Spiegelman B, Wu Z. PPAR {delta} agonism activates fatty acid oxidation via PGC-1{alpha} but does not increase mitochondrial gene expression and function. J Biol Chem 2009; 284: 18624-18633
  CrossrefPubMedGoogle Scholar